wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38404422-A3A4DD03-4B6C-41F2-9F50-FDF784EF378B
Q38404422-A3A4DD03-4B6C-41F2-9F50-FDF784EF378B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38404422-A3A4DD03-4B6C-41F2-9F50-FDF784EF378B
Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?
P2860
Q38404422-A3A4DD03-4B6C-41F2-9F50-FDF784EF378B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38404422-A3A4DD03-4B6C-41F2-9F50-FDF784EF378B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
38c4135fe57d9f81540a31d707b3606ba694db31
P2860
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati